Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
American Journal of Psychiatry – January 01, 2025
Source: OpenAlex
Summary
Psilocybin, a potent hallucinogen and alkaloid studied in chemical synthesis, shows promise for severe treatment-resistant depression. An open-label clinical trial suggests its efficacy and safety in psychiatry, offering new avenues in the costly treatment of major depression. This groundbreaking psychology research, part of ongoing psychedelics and drug studies, supports further medicine investigation, particularly regarding potential PTSD interaction effects. Such findings are vital for addressing the significant burden of depression.
Abstract
This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population, including consideration of PTSD interaction effects.